Results 21 to 30 of about 3,065,291 (226)
Prostate cancer
Nature Reviews Disease Primers, 2021 Screening for prostate cancer is technically feasible. Recent advances in diagnostic strategies have led to a significant stage shift at the time of diagnosis in the direction of disease that is confined to the prostate clinically and histologically. This chapter updates available information relevant to the issue of early detection and screening for ...Sandhu, S, Moore, CM, Chiong, E, Beltran, H, Bristow, RG, Williams, SG +5 more +9 more sourcesKi-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. [PDF]
, 2009 Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed ...A Gopalan, M W Kattan, Scardino, P, V Reuter, C Cooper, J Eastham, Eastham, J., Gopalan, A., Cuzick, J, Gerald, W., Gopalan, A, Reuter, V, Ambroisine, L., D M Berney, Kudahetti, S., H Moller, Scardino, P., Reuter, V., Kudahetti, S, Moller, H, Gerald, W, J Cuzick, Berney, D. M., Moller, H.; id_orcid, Møller, H., Cuzick, J., Berney, DM, L Ambroisine, Fisher, G., Eastham, J, Cooper, C., S Kudahetti, P Scardino, Ambroisine, L, Foster, C. S., Fisher, G, Foster, CS, Cooper, C, W Gerald, G Fisher, C S Foster, Kattan, M. W., Kattan, MW +42 morecore +1 more sourceRisk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
BMC Cancer, 2018 Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won +10 moredoaj +1 more sourceBAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Genome Medicine, 2019 Background Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted ...Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H. Adomat, Dong Lin, Hui Xue, Xin Dong, Robert Shukin, Robert H. Bell, Brian McConeghy, Anne Haegert, Sonal Brahmbhatt, Estelle Li, Htoo Zarni Oo, Antonio Hurtado-Coll, Ladan Fazli, Joshua Zhou, Yarrow McConnell, Andrea McCart, Andrew Lowy, Gregg B. Morin, Tianhui Chen, Mads Daugaard, S. Cenk Sahinalp, Faraz Hach, Stephane Le Bihan, Martin E. Gleave, Yuzhuo Wang, Andrew Churg, Colin C. Collins +32 moredoaj +1 more sourcePrevention and early detection of prostate cancer. [PDF]
, 2014 Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer.Culig, Zoran, Vecchia, Carlo La, Stenzl, Arnulf, P. H. Brown, Meyskens, FL, H. Schmid, Thorat, M.A., Parnes, Howard L., Key, Timothy, Wilt, Timothy J, Rittenhouse, H., Minasian, Lori M, Perner, S. (Sven), Schmid, H-P, Cuzick, J, Minasian, LM, Brawley, Otis W., Ford, Leslie G., G. Andriole, Perner, S, Key, Timothy J., D. Ilic, Ilic, Dragan, Parker, C. (C.), Key, TJ, Andriole, Gerald, Hamdy, Freddie C., R. A. Eeles, Holmberg, Lars, J. Schalken, Eeles, R. (Rosalind), Parker, C, Lilja, Hans, Wolk, Alicja, Holmberg, Lars,, Parnes, Howard L, Tombal, B, T. J. Wilt, Schmitz-Dräger, Bernd J., Schmitz-Draeger, BJ, F. H. Schröder, Hamdy, Freddie C, F. C. Hamdy, Lilja, H, Marberger, Michael, Lund University., Hamdy, FC, Schalken, J, Andriole, G.L. (Gerald), Andriole, G, Cuzick, Jack, Hamdy, F. (Freddie), Schmid, HP, Vecchia, C. La, Schmid, Hans Peter, Ford, L.G., A. Wolk, Tombal, Bertrand, Schmid, H.P., Meyskens, F.L. (Frank L), Schmitz-Dräger, BJ, Wilt, TJ, Schmid, H.-P. (Hans-Peter), Thorat, Mangesh A, Brawley, O.W., T. J. Key, Lilja, H., Schalken, J.A. (Jack), Parker, C., Holmberg, L, Schmitz-Dräger, Bernd J, M. Marberger, La Vecchia, C, Key, T.J. (Timothy J), Brawley, OW, F. L. Meyskens, Eeles, Rosalind A, Schröder, F.H. (Fritz), B. J. Schmitz Dräger, Brown, PH, Parker, Chris, Ilic, D, Ilic, D. (Dragan), Ford, L.G. (Leslie G), C.La Vecchia, Wolk, K. (Kerstin), Tombal, B. (Bertrand), Schmitz-Drager, B.J., Minasian, L.M. (Lori M), L. M. Minasian, Schröder, Fritz H, H. Lilja, B. Tombal, Schalken, J.A., Brown, Powel H, Rittenhouse, H. (Harry), O. W. Brawley, Stenzl, A, C. Parker, Brawley, O.W. (Otis W), Meyskens, Frank L., Vecchia, C.L. (Carlo La), Culig, Z., Brown, P.H., Parnes, HL, Cuzick, J., Wilt, Timothy J., Ford, Leslie G, Z. Culig, Culig, Z. (Zoran), L. G. Ford, Brawley, Otis W, Key, Timothy J, Schmitz-Dräger, B.J. (Bernd J), S. Perner, Marberger, M, Schalken, Jack, Thorat, M.A. (Mangesh A), Hamdy, F.C., Stenzl, A. (Arnulf), Wilt, T.J., Wolk, A, Schroder, F.H., Culig, Z, Key, T.J., Eeles, R.A., Lilja, Hans,, Ford, LG, Lilja, H. (Hans), Parnes, H.L. (Howard L), Eeles, RA, Marberger, M., Andriole, G., Schröder, Fritz H., Schmid, Hans-Peter, Schröder, FH, Stenzl, A., L. Holmberg, Meyskens, F.L., Thorat, Mangesh A., A. Stenzl, Meyskens, Frank L, Brown, P.H. (Powel H), J. Cuzick, La Vecchia, Carlo, H. Rittenhouse, H. L. Parnes, Wolk, A., Rittenhouse, Harry, Perner, Sven, M. A. Thorat, Tombal, B., Schröder, Fritz, Minasian, Lori M., Ilic, D., Minasian, L.M., Parnes, H.L., Rittenhouse, H, Marberger, M. (Michael), Perner, S., Holmberg, L. (Lars), Cuzick, J. (Jack), Wilt, T.J. (Timothy J.), Holmberg, L., Thorat, MA, Eeles, Rosalind A., Brown, Powel H. +166 morecore +2 more sourcesSmall extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biology & Therapy, 2022 The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino +10 moredoaj +1 more sourceHIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition
Frontiers in Cell and Developmental Biology, 2021 Hypoxia is a universal pathological feature of solid tumors. Hypoxic tumor cells acquire metastatic and lethal phenotypes primarily through the activities of hypoxia-inducible factor 1 alpha (HIF1α).Hao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, Christopher T. Harvey, Changhui Xue, Qiong Liu, Sadie Wiens, Sushant K. Kachhap, Tomasz M. Beer, David Z. Qian +9 moredoaj +1 more sourceMir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer [PDF]
, 2013 <p>Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)–extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (CaP). The mechanism Kalna, G., Yang, Z H, Z H Yang, Leung, H.Y., Scardino, P, L B Singh, Singh, LB, H Møller, C Cooper, Cuzick, J, J Fleming, Singh, L.B., Yang, Z.H., I Ahmad, G Kalna, D M Berney, Singh, L. B., Scardino, P., Leung, H Y, Ahmad, I., Møller, H; id_orcid, J Cuzick, Berney, D. M., Cuzick, J., Møller, H., Leung, H. Y., Berney, DM, Fisher, G., Fleming, J., Cooper, C., Leung, HY, Kalna, G, P Scardino, Yang, Z. H., Berney, D.M., Fisher, G, Cooper, C, Møller, H, Ahmad, I, G Fisher, Yang, ZH, Singh, L B, Fleming, J, H Y Leung, Berney, D M +44 morecore +1 more sourceProtocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
BMC Cancer, 2018 Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP +16 moredoaj +1 more source
